Koopmans P P, Thien T, Thomas C M, Van den Berg R J, Gribnau F W
Br J Clin Pharmacol. 1986 Apr;21(4):417-23. doi: 10.1111/j.1365-2125.1986.tb05216.x.
In this double-blind two period crossover study, we investigated the effect of indomethacin and sulindac on blood pressure in 25 hypertensive patients being treated with hydrochlorothiazide. The study consisted of seven 4 week periods. In the first and the last period the patients took placebos, in period two, four and six they were treated with hydrochlorothiazide 50 mg once daily alone, and in the third and fifth period hydrochlorothiazide 50 mg once daily was given in combination with either indomethacin 50 mg twice daily or sulindac 200 mg twice daily in double-blind random order. Blood pressure, measured by sphygmomanometer and arteriosonde, and body weight were determined every 2 weeks. Compared with placebo hydrochlorothiazide decreased the mean arterial pressure by 8%. Addition of both indomethacin and sulindac resulted in only slight and generally similar changes of this blood pressure lowering effect. This was found both for the whole group and when both treatment sequence groups were analysed separately. In contrast to sulindac, indomethacin attenuated the hydrochlorothiazide-induced decreases of body weight, plasma potassium and the increase of plasma renin activity. Both non-steroidal anti-inflammatory drugs (NSAID) reduced the 24 h urinary excretion of prostaglandins (PGs), i.e. PGF2 alpha, 6 ketoPGF1 alpha and thromboxane B2 except PGE2. From this study it can be concluded that, in contrast to sulindac, indomethacin attenuated the diuretic action of hydrochlorothiazide, however apparently without consequences for its long-term blood pressure lowering effect. This study does not support the hypothesis that the difference between the two NSAIDs can be explained by different effects on renal PG synthesis.
在这项双盲两阶段交叉研究中,我们调查了吲哚美辛和舒林酸对25名正在接受氢氯噻嗪治疗的高血压患者血压的影响。该研究包括七个为期4周的阶段。在第一阶段和最后阶段,患者服用安慰剂;在第二、第四和第六阶段,他们单独接受每日一次50毫克氢氯噻嗪的治疗;在第三和第五阶段,每日一次50毫克氢氯噻嗪与每日两次50毫克吲哚美辛或每日两次200毫克舒林酸以双盲随机顺序联合使用。每2周通过血压计和动脉传感器测量血压,并测定体重。与安慰剂相比,氢氯噻嗪使平均动脉压降低了8%。添加吲哚美辛和舒林酸均仅导致这种降压效果出现轻微且总体相似的变化。这在整个组以及分别分析两个治疗顺序组时均得到了证实。与舒林酸不同,吲哚美辛减弱了氢氯噻嗪引起的体重、血钾降低以及血浆肾素活性升高。两种非甾体抗炎药(NSAID)均降低了前列腺素(PGs)的24小时尿排泄量,即除PGE2外的PGF2α、6-酮-PGF1α和血栓素B2。从这项研究可以得出结论,与舒林酸不同,吲哚美辛减弱了氢氯噻嗪的利尿作用,然而显然对其长期降压效果没有影响。这项研究不支持以下假设,即两种NSAID之间的差异可通过对肾PG合成的不同影响来解释。